Walvax Biotechnology Co., Ltd.
300142
Clasificación en acciones
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
Precio por acción
$1.87
Capitalización bursátil
$2.98B
Cambio (1 día)
-3.71%
Cambio (1 año)
14.73%
País
CN
Comercio Walvax Biotechnology Co., Ltd. (300142)
Categoría
Healthcare
Ingresos de Walvax Biotechnology Co., Ltd. (300142)
Ingresos en Jun 2026 TTM: $313.01M
Según los últimos informes financieros de Walvax Biotechnology Co., Ltd., los ingresos actuales de la empresa (TTM) son $313.01M. En 2024, la empresa obtuvo unos ingresos de $386.55M una disminución en comparación con los ingresos del año 2023, que fueron de $581.16M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Walvax Biotechnology Co., Ltd. desde 2007 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $313.01M | -9.14% |
| 2025 | $344.50M | -10.88% |
| 2024 | $386.55M | -33.49% |
| 2023 | $581.16M | -21.19% |
| 2022 | $737.39M | 35.35% |
| 2021 | $544.82M | 21.10% |
| 2020 | $449.89M | 179.41% |
| 2019 | $161.02M | 26.68% |
| 2018 | $127.11M | 23.75% |
| 2017 | $102.71M | 20.66% |
| 2016 | $85.12M | -45.05% |
| 2015 | $154.92M | 33.46% |
| 2014 | $116.08M | 20.76% |
| 2013 | $96.13M | 11.51% |
| 2012 | $86.20M | 15.58% |
| 2011 | $74.58M | 37.20% |
| 2010 | $54.36M | 55.20% |
| 2009 | $35.03M | 29.85% |
| 2008 | $26.97M | 52.25% |
| 2007 | $17.72M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $23.54B | 7,419.13% |
DE
|
|
| $23.73B | 7,482.90% |
DE
|
|
| $29.24B | 9,241.55% |
JP
|
|
| $5.85B | 1,768.57% |
CH
|
|
| $6.34B | 1,926.24% |
IN
|
